Form 4: Perrigo Executive Granted Over 11,000 Restricted Stock Units

Abigail Lennox, Executive Vice President and Chief Strategy Officer of Perrigo Company plc, was granted 11,468 Restricted Stock Units as part of her compensation.

Summary

• Abigail Lennox, EVP and CSO of Perrigo Company plc (PRGO), acquired 11,468 Restricted Stock Units (RSUs) on June 6, 2025.
• Each RSU represents a contingent right to receive one ordinary share of Perrigo Company plc.
• The RSUs will vest in three equal annual installments, with the first vesting occurring on June 6, 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it represents a standard compensation event, the grant of RSUs to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value and aids in executive retention. The minor dilution from future share issuance is a common trade-off.

Positives

• The grant of Restricted Stock Units to a key executive like Abigail Lennox can serve as an incentive for long-term retention and alignment of interests with shareholders.
• The vesting schedule over three years encourages sustained performance and commitment from the executive.

Negatives

• The issuance of new shares upon vesting of RSUs will result in a minor dilution for existing shareholders, though this is a standard component of executive compensation.

Future Outlook

The document does not provide a future outlook beyond the vesting schedule of the granted Restricted Stock Units.

Industry Context

This transaction is a routine executive compensation event within the consumer healthcare and pharmaceutical industry, reflecting standard practices for incentivizing and retaining key leadership.

Comparison to Industry Standards

• The grant of Restricted Stock Units with a multi-year vesting schedule is a common executive compensation practice across the pharmaceutical and consumer healthcare sectors, aligning executive incentives with long-term company performance.
• Companies like Johnson & Johnson (JNJ), Pfizer (PFE), and Procter & Gamble (PG) frequently utilize similar equity-based compensation plans for their senior executives to promote retention and shareholder value creation.

Related Party Transactions

• The transaction involves the grant of equity compensation to a named executive officer, which is a common form of related-party transaction in the context of executive remuneration.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also benefit from executive retention and alignment of interests.
• Employees: Reflects standard compensation practices for senior leadership, potentially setting a precedent for other equity-based incentives.

Next Steps

• The Restricted Stock Units will vest in three equal annual installments, beginning on June 6, 2026.

Key Dates

Keywords

Perrigo Company plc, PRGO, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Executive Compensation, Abigail Lennox, Pharmaceuticals, Consumer Healthcare